|1.||Adam, Albert: 3 articles (11/2011 - 01/2008)|
|2.||Duan, Qing Ling: 2 articles (11/2011 - 04/2009)|
|3.||Rouleau, Guy A: 2 articles (11/2011 - 04/2009)|
|4.||Brown, Nancy J: 2 articles (01/2008 - 02/2002)|
|5.||Akula, A: 2 articles (01/2004 - 12/2003)|
|6.||Veeravalli, K K: 2 articles (01/2004 - 12/2003)|
|7.||Drouet, C: 1 article (05/2014)|
|8.||Beaudouin, E: 1 article (05/2014)|
|9.||Defendi, F: 1 article (05/2014)|
|10.||Moneret-Vautrin, D A: 1 article (05/2014)|
11/01/2011 - "A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema."
11/01/2011 - "Impaired metabolism of bradykinin and des-Arg(9) -bradykinin by aminopeptidase P (APP) is a key contributor to ACEi-angioedema. "
10/01/2002 - "In order to identify patients at risk of angioedema we have recently shown that low plasma levels of aminopeptidase P, another enzyme which cabolises bradykinin, could indicate a predisposition for development of angioedema in some patients treated with vasoinhibitor drugs."
04/01/2009 - "The purpose of this study was to determine whether mutations in F12 and polymorphisms in the genes encoding aminopeptidase P (APP) and angiotensin I-converting enzyme (ACE), which have been associated with increased bradykinin levels, contribute to estrogen-dependent inherited angioedema in a large family of Italian origin. "
01/01/2008 - "Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with angiotensin-converting enzyme inhibitor-associated angioedema. "
01/01/2004 - "We wished to determine the involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions mediated by bradykinin via the combined inhibition of ACE and aminopeptidase P (APP) in an in vivo rat model of acute ischemia (30 min) and reperfusion (4h). "
11/01/2003 - "The aim of the present study was to investigate the involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions mediated by bradykinin via the combined inhibition of angiotensin converting enzyme and aminopeptidase P in an in vivo rat model of acute ischemia (30 min) and reperfusion (4 h). "
12/01/2003 - "We wished to determine the cardioprotective actions of an aminopeptidase P inhibitor, apstatin alone and in combination with enalapril/lisinopril/ramipril in an in vivo rat model of acute ischemia (30 min) and reperfusion (4 h). "
10/01/1999 - "Cardioprotective effects of the aminopeptidase P inhibitor apstatin: studies on ischemia/reperfusion injury in the isolated rat heart."
10/01/1999 - "The results demonstrate that the aminopeptidase P inhibitor apstatin is cardioprotective in this model of cardiac ischemia/ reperfusion injury."
09/01/2001 - "2. Since aminopeptidase P (APP) has been shown to participate in myocardial kinin metabolism to the same extent as ACE, the aims of the present study were to investigate whether (a) inhibition of APP leads to a reduction of myocardial infarct size in a rat model of acute ischaemia and reperfusion, (b) reduction of infarct size is mediated by bradykinin, and (c) a combination of APP and ACE inhibition leads to a more pronounced effect than APP inhibition alone. "
09/01/2001 - "Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway."
01/01/1999 - "Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P."
11/01/2006 - "Although the association of angiotensin I-converting enzyme inhibitors (ACEis) with a negatively charged membrane is thought to be responsible for hypersensitivity reactions (HSRs) during hemodialysis, we hypothesize that these complications are due to changes in plasma aminopeptidase P (APP) activity and genotype. "
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|3.||Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)
|5.||Nitric Oxide (Nitrogen Monoxide)
|6.||Lysine Carboxypeptidase (Carboxypeptidase N)
|10.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|1.||Renal Dialysis (Hemodialysis)